MARCHF10

Across TCGA pan-cancer cohorts, MARCHF10 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MARCHF10 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MARCHF10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MARCHF10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and KIRC are the cancer types where MARCHF10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	33	view →
UCEC	DFS	Median	III,IV	0.915	0.528	.028	18	view →
KIRC	DFS	Median	IV	0.054	0.632	<.001	12	view →
COAD	OS	Median	All	0.153	0.676	.002	10	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →
HNSC	OS	Median	III,IV	0.198	0.745	.003	6	view →
LIHC	DFS	Median	All	0.096	0.555	.002	3	view →
SKCM	DFS	Median	All	0.108	0.216	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MARCHF10–ESCA (OS)

Open the ESCA breakdown →